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Gene expression profiling of lip salivary gland (LSG) has shown that C-X-C motif chemokine 
10 (CXCL10) and matrix metalloproteinase 9 (MMP9) expression is up-regulated in primary 
Sjögren's syndrome (pSS) patients. Although CXCL10 and MMP-9 are both associated with 
pSS pathogenesis, the potential relationship between these two factors has not been investigated. 
In this study, we used LSG sections from pSS patients and human salivary gland cell lines to 
investigate the relationship between CXCL10 and MMP-9. Immunofluorescence analyses 
revealed that CXCL10 and MMP-9 were co-expressed in the LSG of pSS patients, particularly 
in expanded ductal cells. Furthermore, RT-qPCR analyses on human salivary gland ductal NS-
SV-DC cells confirmed that CXCL10 expression was induced by interferon (IFN)-γ, whereas 
that of MMP9 was stimulated by IFN-α, tumor necrosis factor-α, and interleukin-1β. 
Remarkably, MMP-9 inhibition in IFN-γ-stimulated NS-SV-DC cells significantly decreased 
CXCL10 mRNA and secreted protein levels. Further analyses established that MMP-9 
inhibition in IFN-γ-stimulated NS-SV-DC cells decreased STAT1 phosphorylation and hence 
suppressed IFN-γ signaling. Collectively, these results suggest that in addition to its reported 
role in the destruction of acinar structures, MMP-9 is involved in the IFN-γ-induced production 
of CXCL10 in pSS lesions. We believe that our findings open the door to the development of 
novel treatments for pSS, based on the modulation of MMP-9 activity. 
 





Sjögren's syndrome (SS), one of the most common autoimmune diseases [1, 2], is characterized 
by the destruction of the acinar structure by infiltrating mononuclear cells in the salivary and 
lacrimal glands [3-5]. Activated T and B cells constitute the majority of the infiltrating 
mononuclear cells in the lip salivary gland (LSG), while professional antigen-presenting cells, 
such as macrophages and dendritic cells (DCs), are correlated with the severity of the SS lesions 
[4, 5]. The mechanisms underlying the variability of glandular infiltration in SS salivary glands 
remain unclear. However, accumulating evidence indicates that several chemokines contribute 
to the development and progression of SS lesions [6-9]. 
C-X-C motif chemokine 10 (CXCL10) is a CXC chemokine induced by interferon (IFN)-γ 
and is produced by diverse cell types, including peripheral blood mononuclear cells, fibroblasts, 
and endothelial cells, during Th1-type immune responses [10]. Its cognate receptor C-X-C 
motif chemokine receptor 3 (CXCR3) is expressed on a wide range of cells of the innate 
immune system, including DCs, natural killer cells, natural killer T cells, neutrophils, and 
macrophages [11-14]. Therefore, these different cell types should be susceptible to CXCL10-
mediated chemotaxis. Notably, gene expression profiling of LSG in control subjects and 
primary SS (pSS) patients has demonstrated that CXCL10 is up-regulated in the latter [15]. 
Furthermore, CXCL10 is involved in the accumulation of infiltrating T cells in the salivary 
glands of pSS patients [7]. More recently, we reported that CXCL10 is secreted by ductal cells 




Matrix metalloproteinases (MMPs) comprise a growing family of endopeptidases that can 
degrade extracellular matrix components, including collagens, elastin, laminins, and fibronectin, 
and thereby facilitate cell migration and tissue remodeling [16]. Importantly, the formation of 
normal acinar structures in the salivary glands depends on the integrity of the extracellular 
matrix, including the basement membrane [17, 18]. As is the case for CXCL10, MMP9 is over-
expressed in the LSG of pSS patients [19]. Furthermore, previous studies suggest that increased 
MMP-9 activity and expression enhances the destruction of the basement membrane, which 
leads to the destruction of the acinar structures in SS salivary glands [20, 21]. Of note, recent 
studies also indicate that MMP-9 is important for the release of cytokines/chemokines [22, 23]. 
Collectively, these data support the notion that CXCL10 and MMP-9 both play roles in the 
pathogenesis of SS. However, the potential relationship between CXCL10 and MMP-9 has not 
been investigated. In this study, we used both LSG sections from pSS patients and human 
salivary gland cell lines to investigate the impact of MMP-9 activity on the production of 
CXCL10 in the salivary gland. 
 
MATERIALS AND METHODS 
Patients 
Six female patients with pSS (mean age 64.2 ± 13.9 years) and three healthy female subjects 
(mean age 60.3 ± 4.2 years) were enrolled in this study. All individual participants included in 




patients satisfied the revised Japanese Ministry of Health criteria for the diagnosis of SS [24] 
and the American College of Rheumatology classification criteria for SS [25]. The diagnosis of 
SS was based on the presence of two or more of the following clinicopathologic findings: 
lymphocytic infiltration of the salivary or lacrimal glands, dysfunction of salivary secretion, 
keratoconjunctivitis sicca, and presence of anti-Sjögren syndrome antigen A or B 
autoantibodies. The healthy subjects had experienced subjective symptoms of oral dryness but 
met none of the criteria for the diagnosis of SS. 
 
Immunofluorescence Staining 
Formalin-fixed paraffin-embedded LSG sections from pSS patients and healthy subjects were 
deparaffinized in xylene and rehydrated with graded ethanol (100%, 95%, 70%, and 50%). 
Antigen retrieval was performed by microwave treatment using a Citrated-based Antigen 
Unmasking Solution (Vector Laboratories, Burlingame, CA, USA) according to the 
manufacturer’s recommendations. Endogenous biotin was blocked using the Blocking One 
reagent (Nacalai Tesque, Kyoto, Japan) according to the manufacturer’s recommendations. 
Sections were then incubated overnight at 4°C with rabbit polyclonal anti-human CXCL10 
(Abcam, Cambridge, UK) and mouse monoclonal anti-human MMP-9 (Abcam) primary 
antibodies diluted 1:100 in PBS. After three washes with phosphate-buffered saline (PBS), the 
sections were incubated for 1 h at room temperature (RT) with goat anti-mouse IgG (H+L) 




1:200 in PBS. Next, the sections were washed in PBS and incubated for 1 h at RT with goat 
anti-rabbit IgG (H+L) conjugated to Alexa Fluor 568 secondary antibodies (Invitrogen) diluted 
1:200 in. Finally, the nuclei were counterstained using 4',6-diamidino-2-phenylindole (DAPI). 
The sections were observed using a Nikon A1 laser scanning confocal microscope (Nikon, 
Tokyo, Japan) and images were acquired using the NIS-Elements C Software (Nikon). 
 
Cell culture 
The detailed characteristics of the immortalized normal human salivary gland ductal (NS-SV-
DC) and acinar (NS-SV-AC) cell lines have been described elsewhere [26]. Both cell lines were 
cultured in keratinocyte serum-free medium (Gibco, Gaithersburg, MD, USA) in an incubator 
at 37°C with a humidified atmosphere containing 5% CO2. 
 
Reagents 
Recombinant human IFN-α, IFN-γ, tumor necrosis factor (TNF)-α, and interleukin (IL)-1β 
were purchased from R&D Systems (Minneapolis, MN, USA). The MMP-9 inhibitor I was 
purchased from Merck (Darmstadt, Germany). 
 
Real-Time Quantitative Reverse Transcription-Polymerase Chain Reaction (RT-qPCR) 
NS-SV-DC and NS-SV-AC cells were treated for 6, 12, or 24 h with 1000 IU/mL IFN-α, 10 




treated for 6, 12, or 24 h with 10 ng/mL IFN-γ in the presence or absence of 5 μM MMP-9 
inhibitor. Total RNA was isolated using the TRIzol reagent (Life Technologies, Carlsbad, CA, 
USA) according to the manufacturer’s recommendations. Then, total RNA was converted into 
cDNA using the PrimeScript RT reagent Kit (TaKaRa, Kusatsu, Japan) according to the 
manufacturer’s recommendations. The mRNA levels of MMP9, CXCL10, IFN-γ receptor 1 
(IFNGR1), IFNGR2, and GAPDH were analyzed using corresponding Assays-on-Demand 
Gene Expression Products (Applied Biosystems, Tokyo, Japan) and the TaqMan Universal 
PCR Master Mix (Applied Biosystems) with an ABI Prism 7000 Sequence Detection System 
(Applied Biosystems), according to the manufacturer's recommendations. The thermal cycler 
conditions were 95°C for 10 min, followed by 40 cycles of 95°C for 5 s and 60°C for 30 s. Gene 
expression data were analyzed using the 2−ΔΔCT method of the Sequence Detection System 
software version 1 (Applied Biosystems). The relative quantification (RQ) of the fold change 
in gene expression was calculated using the formula RQ = 2−ΔΔCT and normalized using 
GAPDH as an internal reference. The relative mRNA levels are expressed as fold increase 
compared to the GAPDH mRNA level. 
 
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
Specific custom sense and anti-sense primers for IFNGR1 
(5′-GCTGTATGCCGAGATGGAAAA-3′ and 5′-AGGAAAATGGCTGGTATGACG-3′), 




5′-TGGACATAATAACAAAAAAAGGC-3′), and GAPDH 
(5′-ACGCATTTGGCTGTATTGGG-3′ and 5′-TGATTTTGGAGGGATCTCGC-3′) were 
synthesized by Sigma (Deisenhofen, Germany). RT-PCR reactions were performed on a 
LifeECO Thermal Cycler (Nippon Genetics, Tokyo, Japan) using the Ex Taq DNA Polymerase 
(TaKaRa) according to the manufacturer’s recommendations. The thermal cycler conditions 
were 30 cycles of 98°C for 10 s, 55°C for 30 s, and 72°C for 1 min. Amplification products 
were separated by 1.5% agarose gel electrophoresis and visualized after ethidium bromide 
staining using a FAS-III gel imaging system (TOYOBO, Osaka, Japan). 
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
NS-SV-DC cells were incubated for 6, 12, or 24 h with 10 ng/mL IFN-γ in the presence or 
absence of 5 μM MMP-9 inhibitor. The supernatants were collected, and the secreted CXCL10 
protein levels were analyzed using a human CXCL10 ELISA kit (R&D Systems) according to 
the manufacturer’s recommendations. The absorbance at 450 nm was measured using a 
Multiskan JX microplate reader (Thermo Fisher Scientific, Waltham, MA, USA), and CXCL10 
protein levels were determined using a standard curve. 
 
Protein Isolation and Western Blot Analysis 
NS-SV-DC cells were treated for 5, 30, 60, or 120 min with 10 ng/mL IFN-γ in the presence or 




Mammalian Protein Extraction Reagent (Thermo Scientific) and Halt Protease Inhibitor 
Cocktail (Thermo Scientific) according to the manufacturer’s recommendations. Whole-cell 
lysates proteins (20 μg) were separated by electrophoresis using 10% sodium dodecyl sulfate 
(SDS)-polyacrylamide gels (Bio-Rad, Hercules, CA, USA) and then transferred onto 
nitrocellulose membranes. The membranes were blocked with 3% bovine serum albumin in 
Tris-buffered saline containing 0.1% Tween 20 (TBS-T) and incubated for 1 h at RT with anti-
STAT1, anti-phospho-STAT1, anti-JAK2, anti-phospho-JAK2, and anti-β-actin primary 
antibodies (all from Cell Signaling Technology, Beverly, MA, USA) diluted 1:1000 in Can Get 
Signal Solution 1 (TOYOBO). After several washes with TBS-T, the membranes were 
incubated for 1 h at RT with appropriate secondary antibodies (Cell Signaling Technology) 
diluted 1:1000 in Can Get Signal Solution 2 (TOYOBO). The immune complexes were 
visualized using an ECL Western Blotting Detection Reagent (GE Healthcare, 
Buckinghamshire, UK). Densitometric analysis was performed using an Amersham Imager 600 
(GE Healthcare) to determine the relative intensity of the immune complexes, using β-actin as 
an internal reference. 
 
Statistical Analyses 
All statistical analyses were performed using the SPSS Statistics version 15.0 software (IBM, 
Armonk, NY, USA). The data were analyzed using the non-parametric two-tailed Mann-






Expression of CXCL10 and MMP-9 in LSG sections from SS Patients 
To assess the relationship between CXCL10 and MMP-9, we first used immunofluorescence 
staining to examine the expression level and localization of CXCL10 and MMP-9 in the LSG. 
Strikingly, CXCL10 and MMP-9 exhibited intense staining in the expanded ductal cells of pSS 
patients compared to those of healthy subjects (Fig. 1), which indicated increased expression 
of both proteins. Furthermore, inflammatory cells were detectable around the ductal structures 
of the salivary glands that showed CXCL10 and MMP-9 co-expression (Fig. 1a). In contrast, 
the infiltrating inflammatory cells in the LSG of pSS patients did not show positive staining for 
CXCL10 or MMP-9 (Fig. 1). 
 
MMP-9 Expression Following IFN-α, IFN-γ, TNF-α, or IL-1β Stimulation of NS-SV-DC 
or NS-SV-AC Cells 
We have previously shown that IFN-α, IFN-γ, TNF-α, and IL-1β regulate the expression of 
CXCL10 mRNA in NS-SV-DC and NS-SV-AC cells [8]. According to our observation, IFN-γ-
stimulated ductal cells were mainly responsible for CXCL10 overproduction in the salivary 
glands of pSS patients [8]. Therefore, to explore further the relationship between CXCL10 and 
MMP-9, we set out to identify factors that could regulate MMP-9 expression in human salivary 




TNF-α, or IL-1β and MMP9 mRNA levels were examined by RT-qPCR. Remarkably, MMP9 
expression in NS-SV-DC cells increased in response to IFN-α, TNF-α, and IL-1β stimulation 
but not following IFN-γ treatment (Fig. 2). In contrast, we could only detect a marginal increase 
in MMP9 mRNA levels in NS-SC-AC cells treated with IFN-γ, which suggested that MMP-9 
was mainly produced by salivary gland ductal cells. 
 
Effects of MMP-9 Inhibition on CXCL10 Expression and Secretion in IFN-γ-Stimulated 
NS-SV-DC Cells 
Next, we conducted RT-qPCR analyses to explore the potential involvement of MMP-9 in the 
regulation of CXCL10 expression. Remarkably, treatment with an MMP-9 inhibitor 
significantly decreased CXCL10 mRNA levels (p < 0.05) in IFN-γ-stimulated NS-SV-DC cells 
(Fig. 3), which suggested that MMP-9 activity was required for IFN-γ-induced CXCL10 
expression. 
To evaluate further the effects of MMP-9 inhibition, we performed an ELISA to measure 
secreted CXCL10 in the supernatants of NS-SV-DC cells treated with IFN-γ in the presence or 
absence of MMP-9 inhibitor. As anticipated, CXCL10 secretion by IFN-γ-stimulated NS-SV-
DC was massively increased after 24 h (Fig. 4). In contrast, MMP-9 inhibition resulted in a 
significant decrease in the production of CXCL10 after 24 h (p < 0.05), which indicated that 





Effects of MMP-9 Inhibition on IFN-γ Receptors Expression in NS-SV-DC Cells 
Since MMP-9 inhibition suppressed CXCL10 both at the mRNA and protein levels, we 
hypothesized that the MMP-9 inhibitor could affect the IFN-γ receptors (IFNGRs). IFNGRs 
consist of two subunits: IFNGR1 (also known as the IFN-γ receptor α chain) and IFNGR2 (also 
known as the IFN-γ receptor β chain) [27]. We first used RT-PCR to examine the expression 
of IFNGR1 and IFNGR2 in NS-SV-DC cells and found no perceptible difference in the mRNA 
levels following IFN-γ stimulation and MMP-9 inhibition (Fig. 5a). Further analyses using 
RT-qPCR confirmed this observation (Fig. 5b), which indicated that MMP-9 inhibition did not 
significantly affect the mRNA levels of IFNGR1 and IFNGR2. 
 
Effects of MMP-9 Inhibition on the IFN-γ Signaling Pathway in NS-SV-DC Cells 
We previously reported that IFN-γ stimulated the production of CXCL10 via the JAK2/STAT1 
signaling pathway [8]. To dissect the molecular mechanisms underlying the effects of MMP-9 
inhibition, we thus performed western blot analyses to assess the expression levels of STAT1 
and JAK2 and their phosphorylation, which denote STAT1 and JAK2 activation. We did not 
examine JAK1 since our previous report suggested that it was not expressed in NS-SV-DC cells 
[8]. Whether cells were treated or not with the MMP-9 inhibitor, we did not observe any 
changes in JAK2 levels and phosphorylation upon IFN-γ stimulation (Fig. 6a). In striking 




MMP-9 inhibition in IFN-γ-stimulated NS-SV-DC cells (Fig. 6), which indicated that MMP-9 
activity was involved in STAT1-mediated IFN-γ signaling. 
 
DISCUSSION 
Although previous studies reported that CXCL10 and MMP9 were both up-regulated in the LSG 
of pSS patients [15, 19] and MMP-9 was important for the release of cytokines/chemokines [22, 
23], there is, to the best of our knowledge, no study investigating the potential relationship 
between CXCL10 and MMP-9 in SS. Therefore, in this study, we investigated the functional 
relationship between CXCL10 and MMP-9 using LSG sections from pSS patients and human 
salivary gland cell lines. 
SS is a chronic autoimmune disease characterized by the destruction of the salivary and 
lacrimal glands [1-3]. Histologically, pSS patients exhibit selective and progressive destruction 
of the acinar structures in the LSG, which is concomitant with the infiltration of various 
mononuclear cells, including T and B cells, DCs, and macrophages [4, 5]. Although the 
underlying molecular mechanisms leading to mononuclear cell infiltration in the salivary glands 
of pSS patients remain elusive, accumulating evidence indicates that the cytokines-chemokines-
driven network is one of the key processes in the autoimmune response associated with pSS [6-
9, 28]. 
In particular, CXCL10 overexpression has been observed in the ductal epithelium of the 




epithelium regulated immune responses through the recruitment of CXCR3+ mononuclear cells, 
including T cells, DCs, and macrophages [7, 9]. The involvement of MMP-9 in the pathogenesis 
of pSS derives from the observation that increased MMP-9 expression and activity results in 
the disruption of the basement membrane, which in turn leads to the destruction of the acinar 
structures in SS salivary glands [22, 23]. 
Our immunofluorescence analyses in LSG sections from pSS patients showed that 
CXCL10 and MMP-9 were strongly co-expressed in expanded ductal cells, which was 
associated with the presence of infiltrating immune cells around these expanded ductal cells. In 
contrast, CXCL10 and MMP-9 expression was not detected in acinar cells (Fig. 1). A previous 
study reported that CXCL10 increases MMP-9 secretion from monocytes and neutrophils but 
not from lymphocytes in patients with bullous pemphigoid, the most common autoimmune 
subepidermal blistering disease [29]. In contrast, our findings suggested that most of the 
infiltrating immune cells were negative for MMP-9 staining. However, recent studies 
highlighted the role of MMP-9 in the release of cytokines/chemokines [22, 23]. Since we 
observed numerous infiltrating immune cells around the ductal structures that co-expressed 
CXCL10 and MMP-9, we speculated that MMP-9 could be involved in the secretion of 
CXCL10 by ductal cells and, therefore sought to identify the factors that could regulate MMP-9 
expression in human salivary gland ductal and acinar cells. 
The promoter region of the human MMP9 gene includes two AP-1 binding sites, as well as 




various factors, such as TNF-α, IL-1β, PMA, v-src, ras, and LPS. Furthermore, IFN-γ has been 
shown to suppress MMP9 expression through the inhibition of transcription factors, including 
STAT-1α, CREB, and AP-1 [30, 31]. While our RT-qPCR data showing that MMP9 expression 
did not increase in IFN-γ stimulated NS-SV-DC ductal cells are consistent with these reports, 
we also found that MMP9 expression was markedly higher in the NS-SV-DC ductal cell line 
than in the NS-SV-AC acinar cell line. Moreover, we demonstrated that MMP9 expression in 
NS-SV-DC cells increased following IFN-α, TNF-α, or IL-1β stimulation, providing new 
insight into the regulation of MMP-9 in the salivary glands. 
MMPs are known to cleave several pro-inflammatory chemokines, thereby modulating 
their function and having an impact on the inflammatory process [22, 28]. Importantly, MMP-2 
and MMP-9 can cleave CXCL10, which reduces its chemotactic potential through the removal 
of N-terminal residues [32]. Here, we demonstrated that inhibition of MMP-9 activity 
suppressed IFN-γ-induced CXCL10 at both mRNA and secreted protein levels. Although we 
expected MMP-9 to be involved in CXCL10 secretion by NS-SV-DC ductal cells, the 
observation that MMP-9 inhibition affected CXCL10 mRNA transcription was surprising. 
Indeed, our data on IFN-γ signaling established that MMP-9 was not only involved in the 
cleavage of CXCL10 but also in the activation of STAT1, which is known to mediate IFN-γ-
induced CXCL10 expression. 
Based on the evidence available, the progression of pSS is proposed to take place in three 




susceptibility factors. The second is a lymphocyte-independent phase that occurs following the 
release of antigens by necrotic and apoptotic cells or viral trigger, which elicit an innate immune 
response with cytokine production. The third phase is a tissue-specific immunological attack 
by activated T and B cells, and their products, against corresponding self-antigens, which leads 
to autoimmune exocrinopathy [19, 33]. In the second and third phases, salivary gland cells, 
particularly ductal cells, likely produce CXCL10 and MMP-9. Collectively, our findings 
support the notion that MMP-9 could promote the secretion of CXCL10 by ductal cells in SS 
salivary glands via IFN-γ signaling and the activation of STAT1. 
In conclusion, this study provides new insight into the underlying molecular mechanisms 
of SS by demonstrating that MMP-9 inhibition could suppress CXCL10 expression in human 
salivary gland ductal cells via a decrease in STAT1 phosphorylation and, therefore, IFN-γ 
signaling. We would like to propose that in addition to its role in the destruction of acinar 
structures through the degradation of the basement membrane, MMP-9 also contributes to the 
pathogenesis of pSS by supporting the IFN-γ-induced production of CXCL10 in pSS lesions. 
Therefore, we believe that our data provide a strong theoretical basis for the development of 
novel approaches for the treatment of pSS, based on the modulation of MMP-9 activity. 
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Fig. 1 Histological analysis of LSG sections from pSS patients and healthy subjects. 
Representative images (from 3-5 samples) showing immunofluorescence staining for CXCL10 
(green) and MMP-9 (red) in pSS patients (a) and healthy subjects (b). Nuclei (blue) were 
counterstained with DAPI. Arrowheads indicate inflammatory cells. Scale bars = 100 μm. 
 
Fig. 2 MMP9 expression in stimulated NS-SV-DC or NS-SV-AC cells. Histogram showing the 
relative changes in MMP9 mRNA levels in NS-SV-DC or NS-SV-AC cells treated for 6, 12, or 
24 h with 1000 IU/mL IFN-α, 10 ng/mL IFN-γ, 10 ng/mL TNF-α, or 1 ng/mL IL-1β. Untreated 
cells were used as a control (C). Fold changes in mRNA levels were evaluated by RT-qPCR 
using GAPDH mRNA levels as an internal reference. Data are mean values ± standard deviation 
(SD) of three independent experiments. 
 
Fig. 3 Effect of MMP-9 inhibition on CXCL10 expression in IFN-γ-stimulated NS-SV-DC cells. 
Histogram showing the relative changes in CXCL10 mRNA levels in NS-SV-DC cells treated 
for 6, 12, or 24 h with 10 ng/mL IFN-γ in the presence or absence of 5 μM MMP-9 inhibitor. 
Where indicated, cells were cultured in the absence of treatment (control) or with the MMP-9 
inhibitor alone (MMP-9 inhibitor). Fold changes in mRNA levels were evaluated by RT-qPCR 
using GAPDH mRNA levels as an internal reference. Data are mean values ± SD of three 
25 
independent experiments, and asterisks indicate statistical significance for the two-tailed Mann-
Whitney U test (* p < 0.05).
Fig. 4 Effect of MMP-9 inhibition on CXCL10 secretion by the IFN-γ-stimulated NS-SV-DC 
cells. Histogram showing the concentration of CXCL10 measured by ELISA in the supernatants 
of NS-SV-DC cells treated for 6, 12, or 24 h with 10 ng/mL IFN-γ in the presence or absence 
of 5 μM MMP-9 inhibitor. Where indicated, cells were cultured in the absence of treatment 
(control) or with the MMP-9 inhibitor alone (MMP-9 inhibitor). Data are mean values ± SD of 
three independent experiments, and asterisks indicate statistical significance for the two-tailed 
Mann-Whitney U test (* p < 0.05).
Fig. 5 Effects of MMP-9 inhibition on IFN-γ receptors expression in NS-SV-DC cells. (a) RT-
PCR products separated by agarose gel electrophoresis showing the mRNAs levels of IFNGR1
and IFNGR2. GAPDH was used as an internal control. Where indicated, NS-SV-DC cells were 
treated with 10 ng/mL IFN-γ and 5 μM MMP-9 inhibitor. (b) Histogram showing the relative 
changes in IFNGR1 and IFNGR2 mRNA levels in NS-SV-DC cells treated for 6, 12, or 24 h 
with 10 ng/mL IFN-γ in the presence or absence of 5 μM MMP-9 inhibitor. Where indicated, 
cells were cultured in the absence of treatment (control) or with the MMP-9 inhibitor alone 




mRNA levels as an internal reference. Data are mean values ± SD of three independent 
experiments. 
 
Fig. 6 Effects of MMP-9 inhibition on IFN-γ-induced STAT1 and JAK2 phosphorylation in 
NS-SV-DC cells. (a) Representative western blot showing STAT1, JAK2, phosphorylated-
STAT1 (p-STAT1), and phosphorylated-JAK2 (p-JAK2) protein levels in NS-SV-DC cells 
treated for 5, 30, 60, or 120 min with 10 ng/mL IFN-γ in the presence or absence of 5 μM 
MMP-9 inhibitor. β-Actin was used as a loading control. (b) Histogram showing the relative 
STAT1 phosphorylation levels as determined by densitometric analysis of the western blot 
presented in panel (a). The intensity of the p-STAT1 band was normalized to the intensity of 
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